NDC 0074-1065
Skyrizi
Risankizumab-rzaa
Skyrizi is a Kit in the Human Prescription Drug category. It is labeled and distributed by Abbvie Inc.. The primary component is .
| Product ID | 0074-1065_05c4dbfd-4d63-4c5f-950b-cca935a753c3 |
| NDC | 0074-1065 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Skyrizi |
| Generic Name | Risankizumab-rzaa |
| Dosage Form | Kit |
| Marketing Start Date | 2022-09-23 |
| Marketing Category | BLA / |
| Application Number | BLA761105 |
| Labeler Name | AbbVie Inc. |
| Active Ingredient Strength | 0 |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 0074-1065-01
1 KIT in 1 CARTON (0074-1065-01) * 1.2 mL in 1 CARTRIDGE (0074-1066-02) * 1.2 mL in 1 CARTRIDGE (0074-1066-01)
| Marketing Start Date | 2022-09-23 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
NDC Crossover Matching brand name "Skyrizi" or generic name "Risankizumab-rzaa"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0074-1050 | Skyrizi | risankizumab-rzaa |
| 0074-1065 | Skyrizi | Risankizumab-rzaa |
| 0074-1070 | Skyrizi | Risankizumab-rzaa |
| 0074-2042 | Skyrizi | Risankizumab-rzaa |
| 0074-2100 | Skyrizi | risankizumab-rzaa |
Trademark Results [Skyrizi]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 SKYRIZI 87320935 5857879 Live/Registered |
AbbVie Biotechnology Ltd. 2017-02-01 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.